The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gorbakova E.V.

Moscow State University of Food Production

Masyukova S.A.

Moscow State University of Food Production

Ilyina I.V.

Moscow State University of Food Production

Arzumanian V.G.

Mechnikov Research Institute for Vaccines and Sera

The role of the immune system in the pathogenesis of rosacea

Authors:

Gorbakova E.V., Masyukova S.A., Ilyina I.V., Arzumanian V.G.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(4): 112‑116

DOI: 10.17116/klinderma202120041112

Read: 3810 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF THE IMMUNE SYSTEM IN THE PATHOGENESIS OF ROSACEA
THE ROLE OF THE IMMUNE SYSTEM IN THE PATHOGENESIS OF ROSACEA

To cite this article:

Gorbakova EV, Masyukova SA, Ilyina IV, Arzumanian VG. The role of the immune system in the pathogenesis of rosacea. Russian Journal of Clinical Dermatology and Venereology. 2021;20(4):112‑116. (In Russ.)
https://doi.org/10.17116/klinderma202120041112

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
To the Question of Metronidazole Effe­ctiveness in Rosa­cea Therapy. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):740-743
Clinical and anamnestic features of rosa­cea in women in peri­menopausal period. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):49-55
Damage of human skin barrier components in expo­sure of Demo­dex specimens. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):219-226
Expe­rience of comprehensive treatment of erythematotelangiectatic rosa­cea. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):236-239
Angiopausin concentrate for skin prone to redness. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):369-374
Features of pero­xide-antioxidant imba­lance in patients with rosa­cea and approaches to comprehensive therapy. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):439-444
The role of substance P in modu­lation of inflammation and immune response: from neurotransmitter to therapeutic target. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):566-572
Comparative evaluation of gamma inte­rferen tests in vitro for dete­ction of cell-mediated immune response to reco­mbinant Myco­bacterium Tube­rculosis anti­gens in dete­ction of tube­rculosis infe­ction. Labo­ratory Service. 2025;(1):13-20
Abstract:

Rosacea is an inflammatory skin disease clinically manifested by erythema, telangiectasias and inflammatory elements that affects mainly the central part of the face and is characterized by a chronic and progressive course and resistance to therapy. Currently, rosacea is considered as a multifactorial disease with a large number of exogenous and endogenous trigger factors. In the development of the inflammatory process in rosacea the immune system is of great importance according to some scientists, the imbalance of the innate and adaptive immune response may be central to the pathogenesis of dermatosis. The treatment strategy at the present stage is aimed at eliminating immune inflammation and reducing the activity of proteases possibly due to comorbid factors.

OBJECTIVE

Determine the most significant immunological markers in rosacea immunogenesis.

MATERIAL AND METHODS

Analysis of publications related to the study of immune disorders in patients with rosacea.

RESULTS

According to the literature, certain disorders of the immune system were found in the majority of patients with rosacea. The main manifestations of immune disorders are expressed in an imbalance of pro-inflammatory and immunoregulatory cytokines, serine proteases, antimicrobial peptides (cathelicidin, beta-defensins) and toll-like receptors.

CONCLUSION

Having considered the peculiarities of the dysregulation of the immune system in patients with rosacea, it is possible to conclude the involvement of both cellular and humoral immunity with Th1/Th17 (T-helper cells, Th) in the pathophysiological mechanisms of the disease. Also, polarization of the immune response, an increase in the level of proinflammatory cytokines IL-1, IL-6, IL-8, as well as an increase in the production of classes of immunoglobulins G, A, M, circulating immune complexes, C-reactive protein in blood serum are involved.

Keywords:

rosacea
immune regulation
cellular immunity
humoral immunity

Authors:

Gorbakova E.V.

Moscow State University of Food Production

Masyukova S.A.

Moscow State University of Food Production

Ilyina I.V.

Moscow State University of Food Production

Arzumanian V.G.

Mechnikov Research Institute for Vaccines and Sera

Received:

04.06.2020

Accepted:

25.05.2021

Close metadata

References:

  1. Buddenkotte J and Steinhoff M. Recent advances in understanding and managing rosacea [version 1; peer review: 3 approved]. F1000Research 2018, 7(F1000 Faculty Rev):1885. https://doi.org/10.12688/f1000research.16537.1
  2. Potekaev NN, Novozhilova OL, Potapova SV, Khamaganova IV. Asymmetric rosacea. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2019;18(2):150-153. (In Russ.). https://doi.org/10.17116/klinderma201918021150
  3. Samcov AV. Akne i akneformnye dermatozy. M. 2014. (In Russ.).
  4. Demina OM, Butov US. Clinical-immunological indicators among patients with rosacea and PDT high-tech healing method application results estimation. Vestnik jesteticheskoj mediciny. 2010;4(9):59-64. (In Russ.).
  5. Zhukova OV, Mimov AV, Kruglova LS, Pomerancev ON, Shustov SA. Laser technologies in the correction of vascular changes. Vestnik poslediplomnogo medicinskogo obrazovanija. 2012;1:5-15. (In Russ.).
  6. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical,cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2-11. 
  7. Tan J, Almeida LMC, Bewley A, Cribier B, Dlova NC, Gallo R, Kautz G, Mannis M, Oon HH, Rajagopalan M, Steinhoff M, Thiboutot D, Troielli P, Webster G, Wu Y, van Zuuren EJ, Schaller M. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. British journal of dermatology. 2017; 176(2):431‐438. 
  8. Del Rosso JQ, Thiboutot D, Gallo RL, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92:234-240. 
  9. Fleischer AB, Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620. 
  10. Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40-47. 
  11. Meyer-Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc. 2011;15:16-23. 
  12. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15:12-15. 
  13. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55:77-81. 
  14. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131:688-697. 
  15. Aloi F, Tomasini C, Soro E, et al. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol. 2000;42:468-472. 
  16. Brown TT, Choi EY, Thomas DG et al. Comparative analysis of rosacea and cutaneous lupus erythematosus: histopathologic features, T-cell subsets, and plasmacytoid dendritic cells. J Am Acad Dermatol. 2014;71:100-107. 
  17. Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med. 1997; 90:144-150. 
  18. Rufli T, Buchner SA. T-cell subsets in acne rosacea lesions and the possible role of Demodex folliculorum. Dermatologica. 1984;169:1-5. 
  19. Smith JR, Lanier VB, Braziel RM, et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91:226-229. 
  20. Buhl T, Sulk M, Nowak P, et al. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. J Invest Dermatol. 2015;135(9):2198-2208.
  21. Chen X, Takai T, Xie Y, et al. Human antimicrobial peptide LL-37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes. Biochem Biophys Res Commun. 2013;433:532-537. 
  22. Sakabe J, Umayahara T, Hiroike M, et al.Calcipotriol increases hCAP18 mRNA expression but inhibits extracellular LL37 peptide production in IL-17/IL-22-stimulated normal human epidermal keratinocytes. Acta Derm Venereol. 2014;94:512-516. 
  23. Moura AKA, et al. Inate immunity in rosacea. Langerhans cells, plasmacytoid dentritic cells, Toll-like receptors and inducible oxide nitric synthase (iNOS) expression in skin specimens: case-control study. Arch Dermatol Res. 2018;10(2):139-146. 
  24. Khayrutdinov VR. Rosacea: modern concepts of the pathogenesis, clinical picture and treatment. Dermatovenerol. kosmetol. 2014;19:32-37. (In Russ.).
  25. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. JAAD. 2013;69(4):570-577. 
  26. Muto Y, Wang Z, Vanderberghe M, et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014; 134(11):2728-2736.
  27. Kalyuzhnaya LD, et al. Manifestations of the immune response in patients with various clinical forms of rosacea. Dermatologiya i venerologiya. 2005; 2:38-42. 
  28. Yarmolik ES, Haretskaya MV, Khvoryk DF, Shulika VR. Characteristic of cytokine status in complex treatment of rosacea. Journal of Grodno State Medical University. 2016;1:39-44. (In Russ.).
  29. Slesarenko NA, Leonova MA, Zaharova NB, Slesarenko NS, Reznikova MA. The role of vascular disorders in the genesis and maintenance of inflammation in the pathogenesis of rosacea. Saratov Journal of Medical Scientific Research. 2012;8(2):650-654. (In Russ.).
  30. Yarmolik ES, Haretskaya MV, Khvoryk DF. Role of angiogenesis and inflammation in the pathogenesis of rosacea. Medical Journal. 2016;1:145-148. (In Russ.).
  31. Rossi JF. Interleukin-6 as a therapeutic target in cancer and immunopathology. Immunology Hematopoiesis. 2012;10:8-24. (In Russ.).
  32. Yao C, Oh J, Lee DH, et al. Toll-like receptor family members in skin fibroblasts are functional and have a higher expression compared to skin keratinocytes. Int J Mol Med. 2015;35(5):1443-1450.
  33. Davydova AV, Bakulev AL, Morrison AV, Leonova MA. Molecular mechanisms of rosacea pathogenesis (review). Saratov Journal of Medical Scientific Research. 2013;3(9):561-565. (In Russ.).
  34. Olisova OJu, Dodina MI, Kushlinskij NE. The role of vascular endothelial growth factor in pathogenesis of rosacea and its medicamental correction. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2012;1:49-55. (In Russ.).
  35. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol. 2003;39:225-237. 
  36. Demina OM, Potekaev NN. Modern etiopathogenic mechanisms of the development of rosacea and new therapies. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2017;3: 13. (In Russ.). https://doi.org/10.17116/klinderma201716313-23
  37. Potekaev NN, Aravskaya ER, Sokolovsky EV, et al. Acne and rosacea. Ed. Potekaeva N.N. M.: Binom; 2007. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.